Abstract
Glioma is still one of the most aggressive forms of brain tumors. Understanding of the biological and pathophysiological mechanisms of survival can help the researchers to develop new management modalities. Industrial toxins could be one of the most important causes for brain tumors, such as dioxin and other aryl hydrocarbon receptor (AhR) ligands. Toxicity of these compounds includes a series of cellular events starting from binding with AhR and ending with the increased expression of a group of xenobiotic metabolizing enzymes (XME) such as the cytochrome P450 (CYPs), CYP1A1, CYP1A2, and CYP1B1. Therefore, identification of the localizations and expressions of the AhR and its regulated CYPs in the central nervous system (CNS) and neuronal cells is of major importance in understanding their physiological and pathological roles. Generally, low but significant level of CYPs expression is demonstrated in the brain in a tissue- and species-specific manner. Moreover, most, but not all, AhR-regulated CYPs are expressed differently in most of the neuronal and glial cells. Although the exact mechanisms of AhR-mediated glioma and neurotoxicity are not fully understood, the present review proposes several mechanisms which include generating reactive oxygen species, activating glutamate receptors, peroxisome proliferator- activated receptors, histone acetylation, and signal transducer and activator of transcription 3.
Keywords: Glioma, Aryl hydrocarbon receptor, CYP1A1, CYP1B1, Glutamate receptor, Histone acetylation, STAT3, and PPAR.
Current Pharmaceutical Design
Title:The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Volume: 19 Issue: 40
Author(s): Hesham M. Korashy, Hatim M. Abuohashish and Zaid H. Maayah
Affiliation:
Keywords: Glioma, Aryl hydrocarbon receptor, CYP1A1, CYP1B1, Glutamate receptor, Histone acetylation, STAT3, and PPAR.
Abstract: Glioma is still one of the most aggressive forms of brain tumors. Understanding of the biological and pathophysiological mechanisms of survival can help the researchers to develop new management modalities. Industrial toxins could be one of the most important causes for brain tumors, such as dioxin and other aryl hydrocarbon receptor (AhR) ligands. Toxicity of these compounds includes a series of cellular events starting from binding with AhR and ending with the increased expression of a group of xenobiotic metabolizing enzymes (XME) such as the cytochrome P450 (CYPs), CYP1A1, CYP1A2, and CYP1B1. Therefore, identification of the localizations and expressions of the AhR and its regulated CYPs in the central nervous system (CNS) and neuronal cells is of major importance in understanding their physiological and pathological roles. Generally, low but significant level of CYPs expression is demonstrated in the brain in a tissue- and species-specific manner. Moreover, most, but not all, AhR-regulated CYPs are expressed differently in most of the neuronal and glial cells. Although the exact mechanisms of AhR-mediated glioma and neurotoxicity are not fully understood, the present review proposes several mechanisms which include generating reactive oxygen species, activating glutamate receptors, peroxisome proliferator- activated receptors, histone acetylation, and signal transducer and activator of transcription 3.
Export Options
About this article
Cite this article as:
Korashy M. Hesham, Abuohashish M. Hatim and Maayah H. Zaid, The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/13816128113199990583
DOI https://dx.doi.org/10.2174/13816128113199990583 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry New Trends of Deep Learning in Clinical Cardiology
Current Bioinformatics The Potential Roles of Magnetic Resonance Spectroscopy and Perfusion- Weighted Imaging in the Grading of Cerebral Gliomas
Current Medical Imaging Stem Cells in Brain Tumorigenesis and their Impact on Therapy
Current Stem Cell Research & Therapy Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Vitamins for Cancer Prevention and Treatment: An Insight
Current Molecular Medicine Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Current Pharmaceutical Design Perfusion MRI of Brain Neoplams
Current Medical Imaging Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Biocatalytic Synthesis of Terpene Esters and their Biological Activity in Human Glioma Cells
Current Pharmaceutical Biotechnology